Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Studies describe new findings in Breast Cancer research
January 26th, 2006
Investigators in France, Finland and the United Kingdom have published new Breast Cancer data. Study 1: Capecitabine/docetaxel combination therapy was deemed a cost-effective treatment in advanced or metastatic breast cancer (MBC) in France. In a recent article published in the journal Bulletin du Cancer, scientists in France detailed a study conducted "to estimate the cost-effectiveness ratio of adopting capecitabine/docetaxel combination therapy in place of docetaxel alone, in France, in patients with MBC, resistant to, or relapsing after anthracycline-containing therapy, The SO 14999 trial is a multicenter trial, randomized, including 511...
Source: Women's Health Weekly (2006-01-26)
|
